Human urine biomarkers of renal cell carcinoma evaluated by ClinProt

Proteomics - Clinical Applications

Volumn 2, Issue 7-8, 2008, Pages 1036-1046

  Bosso, Niccolò ^a   Chinello, Clizia ^a   Picozzi, Stefano Carlo Maria ^c   Gianazza, Erica ^a   Mainini, Veronica ^a   Galbusera, Carmen ^a   Raimondo, Francesca ^a   Perego, Roberto ^a   Casellato, Stefano ^c   Rocco, Francesco ^c   Ferrero, Stefano ^c   Bosari, Silvano ^c   Mocarelli, Paolo ^a,b   Kienle, Marzia Galli ^a   Magni, Fulvio ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b DESIO HOSPITAL   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Biological fluids; Biomarkers; ClinProt; MS; Renal cell carcinoma

Indexed keywords

BIOLOGICAL MARKER;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CLINICAL TRIAL; CLINPROT TECHNIQUE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EARLY DIAGNOSIS; FEMALE; HUMAN; KIDNEY CARCINOMA; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PURIFICATION; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SENSIBILITY; SENSITIVITY AND SPECIFICITY; URINALYSIS;

EID: 50849117189     PISSN: 18628346     EISSN: None     Source Type: Journal    
DOI: 10.1002/prca.200780139     Document Type: Article

References (49)

1. Chow, W. H., Devesa, S. S., Warren, J. L., Fraumeni, J. F. Jr., Rising incidence of renal cell cancer in the United States. JAMA 1999, 281, 1628-1631.
2. Jemal, A., Murray, T., Ward, E., Samuels, A. et al., Cancer statistics, 2005. CA Cancer J. Clin. 2005, 55, 10-30.
3. Motzer, R. J., Bander, N. H., Nanus, D. M., Renal-cell carcinoma. N. Engl. J. Med. 1996, 335, 865-875.
4. Skates, S., Iliopoulos, O., Molecular markers for early detection of renal carcinoma: Investigative approach. Clin. Cancer Res. 2004, 10, 6296S-6301S.
5. Baltaci, S., Aksoy, H., Turkolmez, K., Elhan, A. H. et al., Use of percent free prostate-specific antigen density to improve the specificity for detecting prostate cancer in patients with normal rectal examinations and intermediate prostate-specific antigen levels. Urol. Int. 2003, 70, 36-41.
6. Brawer, M. K., Clinical usefulness of assays for complexed prostate-specific antigen. Urol. Clin. North Am. 2002, 29, 193-203, xi.
7. Swets, J. A., Measuring the accuracy of diagnostic systems. Science 1988, 240, 1285-1293.
8. Unwin, R. D., Harnden, P., Pappin, D., Rahman, D. et al., Serological and proteomic evaluation of antibody responses in the identification of tumor antigens in renal cell carcinoma. Proteomics 2003, 3, 45-55.
9. Ketterlinus, R., Hsieh, S. Y., Teng, S. H., Lee, H., Pusch, W., Fishing for biomarkers: Analyzing mass spectrometry data with the new ClinProTools software. Biotechniqees 2005, Suppl, 37-40.
10. Rogers, M. A., Clarke, P., Noble, J., Munro, N. P. et al., Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: Identification of key issues affecting potential clinical utility. Cancer Res. 2003, 63, 6971-6983.
11. Tolson, J., Bogumil, R., Brunst, E., Beck, H. et al., Serum protein profiling by SELDI mass spectrometry: Detection of multiple variants of serum amyloid alpha in renal cancer patients. Lab. Invest. 2004, 84, 845-856.
12. Won, Y., Song, H. J., Kang, T. W., Kim, J. J. et al., Pattern analysis of serum proteome distinguishes renal cell carcinoma from other urologic diseases and healthy persons. Proteamics 2003, 3, 2310-2316.
13. Hara, T., Honda, K., Ono, M., Naito, K. et al., Identification of two serum biomarkers of renal cell carcinoma by surface enhanced laser desorption/ionization mass spectrometry. J. Urol. 2005, 174, 1213-1217.
14. Engwegen, J. Y., Mehra, N., Haanen, J. B., Bonfrer, J. M. et al., Validation of SELDI-TOF MS serum protein profiles for renal cell carcinoma in new populations. Lab. Invest. 2007, 87, 161-172.
15. Cheng, A. J., Chen, L. C., Chien, K. Y., Chen, Y. J. et al., Oral cancer plasma tumor marker identified with bead-based affinity-fractionated proteomic technology. Clin. Chem. 2005, 51, 2236-2244.
16. Tolson, J. P., Flad, T., Gnau, V., Dihazi, H. et al., Differential detection of S100A8 in transitional cell carcinoma of the bladder by pair wise tissue proteomic and immunohistochemical analysis. Proteomics 2006, 6, 697-708.
17. Klade, C. S., Proteomics approaches towards antigen discovery and vaccine development. Curr. Opin. Mol. Ther. 2002, 4, 216-223.
18. Magni, F., Sarto, C., Valsecchi, C., Casellato, S. et al., Expanding the proteome two-dimensional gel electrophoresis reference map of human renal cortex by peptide mass fingerprinting. Proteomics 2005, 5, 816-825.
19. Seliger, B., Dressler, S. P., Lichtenfels, R., Keliner, R., Candidate biomarkers in renal cell carcinoma. Proteomics 2007, 7, 4601-4612.
20. Gires, O., Munz, M., Schaffrik, M., Kieu, C. et al., Profile identification of disease-associated humoral antigens using AMIDA, a novel proteomics-based technology. Cell. Mol. Life Sci. 2004, 61, 1198-1207.
21. Sarto, C., Valsecchi, C., Magni, F., Tremolada, L. et al., Expression of heat shock protein 27 in human renal cell carcinoma. Proteomics 2004, 4, 2252-2260.
22. Sarto, C., Frutiger, S., Cappellano, F., Senchez, J. C. et al., Modified expression of plasma glutathione peroxidase and manganese superoxide dismutase in human renal cell carcinoma. Electrophoresis 1999, 20, 3458-3466.
23. Lichtenfels, R., Kellner, R., Atkins, D., Bukur, J. et al., Identification of metabolic enzymes in renal cell carcinoma utilizing PROTEOMEX analyses. Biochim. Biophys. Acta 2003, 1646, 21-31.
24. Craven, R. A., Hanrahan, S., Totty, N., Harnden, P. et al., Proteomic identification of a role for the von Hippel Lindau tumour suppressor in changes in the expression of mitochondrial proteins and septin 2 in renal cell carcinoma. Proteomics 2006, 6, 3880-3893.
25. Seliger, B., Fedorushchenko, A., Brenner, W., Ackermann, A. et al., Ubiquitin COOH-terminal hydrolase 1: A biomarker of renal cell carcinoma associated with enhanced tumor cell proliferation and migration. Clin. Cancer Res. 2007, 13, 27-37.
26. Unwin, R. D., Craven, R. A., Harnden, P., Hanrahan, S. et al., Proteomic changes in renal cancer and co-ordinate demonstration of both the glycolytic and mitochondrial aspects of the Warburg effect. Proteomics 2003, 3, 1620-1632.
27. Dallmann, K., Junker, H., Balabanov, S., Zimmermann, U. et al., Human agmatinase is diminished in the clear cell type of renal cell carcinoma. Int. J. Cancer 2004, 108, 342-347.
28. Kellner, R., Lichtenfels, R., Atkins, D., Bukur, J. et al., Targeting of tumor associated antigens in renal cell carcinoma using proteome-based analysis and their clinical significance. Proteomics 2002, 2, 1743-1751.
29. Sarto, C., Marocchi, A., Sanchez, J. C., Giannone, D. et al., Renal cell carcinoma and normal kidney protein expression. Electrophoresis 1997, 18, 599-604.
30. Petricoin, E. F., Liotta, L. A., SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. Curr. Opin. Biotechnol. 2004, 15, 24-30.
31. Koopmann, J., Zhang, Z., White, N., Rosenzweig, J. et al., Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin. Cancer Res. 2004, 10, 860-868.
32. Merchant, M., Weinberger, S. R., Recent advancements in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis 2000, 21, 1164-1177.
33. Lam, T., Nabi, G., Potential of urinary biomarkers in early bladder cancer diagnosis. Expert Rev. Anticancer Ther. 2007, 7, 1105-1115.
34. Pieper, R., Gatlin, C. L., McGrath, A. M., Makusky, A. J. et al., Characterization of the human urinary proteome: A method for high-resolution display of urinary proteins on two-dimensional electrophoresis gels with a yield of nearly 1400 distinct protein spots. Proteomics 2004, 4, 1159-1174.
35. Davis, M. T., Spahr, C. S., McGinley, M. D., Robinson, J. H. et al., Towards defining the urinary proteome using liquid chromatography-tandem mass spectrometry. II. Limitations of complex mixture analyses. Proteomics 2001, 1, 108-117.
36. Wittke, S., Fliser, D., Haubitz, M., Bartel, S. et al., Determination of peptides and proteins in human urine with capillary electrophoresis-mass spectrometry, a suitable tool for the establishment of new diagnostic markers. J. Chromatogr. A 2003, 1013, 173-181.
37. Liu, B. C., Zhang, L., Lv, L. L., Wang, Y. L. et al., Application of antibody array technology in the analysis of urinary cytokine profiles in patients with chronic kidney disease. Am. J. Nephrol. 2006, 26, 483-490.
38. Thongboonkerd, V., Songtawee, N., Sritippayawan, S., Urinary proteome profiling using microfluidic technology on a chip. J. Proteome Res. 2007, 6, 2011-2018.
39. Liangos, O., Perianayagam, M. C., Vaidya, V. S., Han, W. K. et al., Urinary N-acetyl-beta-(D)-glucosaminidase activity and kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure. J. Am. Soc. Nephrol. 2007, 18, 904-912.
40. Fetsch, P. A., Simone, N. L., Bryant-Greenwood, P. K., Marincola, F. M. et al., Proteomic evaluation of archival cytologic material using SELDI affinity mass spectrometry: Potential for diagnostic applications. Am. J. Clin. Pathol. 2002, 118, 870-876.
41. von Eggeling, F., Junker, K., Fiedle, W., Wollscheid, V. et al., Mass spectrometry meets chip technology: A new proteomic tool in cancer research? Electrophoresis 2001, 22, 2898-2902.
42. Pennica, D., Kohr, W. J., Kuang, W. J., Glaister, D. et al., Identification of human uromodulin as the Tamm-Horsfall urinary glycoprotein. Science 1987, 236, 83-88.
43. Shihabi, Z. K., Hinsdale, M. E., Bleyer, A. J., Analysis of Tamm-Horsfall protein by high-performance liquid chromatography with native fluorescence. J. Chromatogr. A 2004, 1027, 161-166.
44. Weichhart, T., Zlabinger, G. J., Saemann, M. D., The multiple functions of Tamm-Horsfall protein in human health and disease: A mystery clears up. Wien. Klin. Wochenschr. 2005, 117, 316-322.
45. Serafini-Cessi, F., Malagolini, N., Cavallone, D., Tamm-Horsfall glycoprotein: Biology and clinical relevance. Am. J. Kidney Dis. 2003, 42, 658-676.
46. Hart, T. C., Gorry, M. C., Hart, P. S., Woodard, A. S. et al., Mutations of the UMOD gene are responsible for medullary cystic kidney disease 2 and familial juvenile hyperuricaemic nephropathy. J. Med. Genet. 2002, 39, 882-892.
47. Bleyer, A. J., Hart, T. C., Shihabi, Z., Robins, V., Hoyer, J. R., Mutations in the uromodulin gone decrease urinary excretion of Tamm-Horsfall protein. Kidney Int. 2004, 66, 974-977.
48. Fowler, J. E. Jr., Frierson, H. F. Jr., Mills, S. E., Mariano, M., Serum antibody against Tamm-Horsfall protein in patients with renal cell carcinoma. Cancer 1987, 59, 1923-1926.
49. Mischak, H., Kaiser, T., Walden, M., Hillmann, M. et al., Proteomic analysis for the assessment of diabetic renal damage in humans. Clin. Sci. (Lond.) 2004, 107, 485-495.